



Clinical trial results:

THE EFFECT OF STATINS TREATMENT ON HIV-1-INFECTED PATIENTS INTERRUPTING ANTIRETROVIRAL THERAPY

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2004-004802-26 |
| Trial protocol | ES |
| Global end of trial date | 31 December 2005 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 16 February 2018 |
| First version publication date | 16 February 2018 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | SIM-ATOR |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Fundació Lluita contra la SIDA |
| Sponsor organisation address | Crta de Canyet s/n, Badalona, Spain, 08916 |
| Public contact | CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14, sgel@flsida.org |
| Scientific contact | CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 31 December 2005 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 December 2005 |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 December 2005 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate if treatment with statins (atorvastatina or simvastatina), in the short (4 weeks) term inhibits the viral replication of the VIH after the interruption of the highly active antiretroviral treatment (HAART).

Protection of trial subjects:

not specific

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 01 June 2005 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Spain: 41 |
| Worldwide total number of subjects | 41 |
| EEA total number of subjects | 41 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 41 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Eligible subjects were chronically HIV-1-infected patients with viral loads of less than 50 copies/ml and CD4 cell counts of 500 cells/ml or greater during the past 6 months of HAART.

Pre-assignment

Screening details:

41 patients were enrolled in the clinical trial.

Period 1

| | |
|------------------------------|--------------------------|
| Period 1 title | overall (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Control group |

Arm description:

interrupted HAART

| | |
|---|-----------------|
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |

| | |
|------------------|--------------|
| Arm title | Ator40 group |
|------------------|--------------|

Arm description:

interrupted HAART + atorvastatin 40mg/day

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | atorvastatine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

40 mg/day

| | |
|------------------|--------------|
| Arm title | Ator80 group |
|------------------|--------------|

Arm description:

interrupted HAART + atorvastatine 80mg/day

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | atorvastatine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

80 mg/day

| Number of subjects in period 1 | Control group | Ator40 group | Ator80 group |
|---------------------------------------|---------------|--------------|--------------|
| Started | 15 | 13 | 13 |
| Completed | 10 | 6 | 9 |
| Not completed | 5 | 7 | 4 |
| safety reasons | 4 | 3 | 3 |
| Adverse event, non-fatal | - | 4 | 1 |
| Lost to follow-up | 1 | - | - |

Baseline characteristics

Reporting groups

| | |
|--|---------------|
| Reporting group title | Control group |
| Reporting group description: interrupted HAART | |
| Reporting group title | Ator40 group |
| Reporting group description: interrupted HAART + atorvastatin 40mg/day | |
| Reporting group title | Ator80 group |
| Reporting group description: interrupted HAART + atorvastatine 80mg/day | |

| Reporting group values | Control group | Ator40 group | Ator80 group |
|---|---------------|--------------|--------------|
| Number of subjects | 15 | 13 | 13 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 15 | 13 | 13 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous Units: years | | | |
| median | 41 | 39 | 40 |
| inter-quartile range (Q1-Q3) | 32 to 54 | 34 to 46 | 33 to 61 |
| Gender categorical Units: Subjects | | | |
| Female | 3 | 4 | 1 |
| Male | 12 | 9 | 12 |

| Reporting group values | Total | | |
|---|-------|--|--|
| Number of subjects | 41 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 41 | | |

| | | | |
|-------------------|---|--|--|
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |

| | | | |
|------------------------------|----|--|--|
| Age continuous | | | |
| Units: years | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 8 | | |
| Male | 33 | | |

End points

End points reporting groups

| | |
|--|---------------|
| Reporting group title | Control group |
| Reporting group description: interrupted HAART | |
| Reporting group title | Ator40 group |
| Reporting group description: interrupted HAART + atorvastatin 40mg/day | |
| Reporting group title | Ator80 group |
| Reporting group description: interrupted HAART + atorvastatine 80mg/day | |

Primary: plasma HIV-1-RNA level

| | |
|--|------------------------|
| End point title | plasma HIV-1-RNA level |
| End point description: | |
| End point type | Primary |
| End point timeframe: from baseline to week 4 and from baseline to week 12 | |

| End point values | Control group | Ator40 group | Ator80 group | |
|---------------------------------------|------------------------|--------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 15 | 13 | 13 | |
| Units: copies/ml | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| baseline | 50 (50 to 50) | 50 (50 to 50) | 50 (50 to 50) | |
| week 4 | 20000 (2500 to 100000) | 130000 (40000 to 200000) | 12000 (8000 to 125000) | |
| week 12 | 16500 (6000 to 18000) | 8600 (2000 to 20000) | 18000 (8500 to 25000) | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Comparing medians differences between groups |
| Statistical analysis description: Comparing medians differences: BI vs week 4 | |
| Comparison groups | Ator40 group v Ator80 group |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 26 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | < 0.05 |
| Method | Wilcoxon (Mann-Whitney) |

Secondary: total serum cholesterol

| | |
|--|-------------------------|
| End point title | total serum cholesterol |
| End point description: | |
| End point type | Secondary |
| End point timeframe: from baseline to week 12 | |

| End point values | Control group | Ator40 group | Ator80 group | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 15 | 13 | 13 | |
| Units: mg/dl | | | | |
| number (not applicable) | | | | |
| baseline | 201 | 213 | 217 | |
| week 12 | 168 | 109 | 128 | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Comparing medians differences between groups |
| Statistical analysis description: Comparing medians differences : BL vs week 12 | |
| Comparison groups | Control group v Ator40 group |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | < 0.05 |
| Method | Wilcoxon (Mann-Whitney) |

| | |
|---|--|
| Statistical analysis title | Comparing medians differences between groups |
| Statistical analysis description: Comparing medians differences : BL - week 12 | |
| Comparison groups | Ator80 group v Control group |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | < 0.05 |
| Method | Wilcoxon (Mann-Whitney) |

Adverse events

Adverse events information

Timeframe for reporting adverse events:
from baseline to week 12

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|--------------------|----------------------|
| Dictionary name | DAIDS AE GRADING TAB |
| Dictionary version | 1.0 |

Reporting groups

| | |
|-----------------------|--------------|
| Reporting group title | Ator40 group |
|-----------------------|--------------|

Reporting group description: -

| | |
|-----------------------|--------------|
| Reporting group title | Ator80 group |
|-----------------------|--------------|

Reporting group description: -

| Serious adverse events | Ator40 group | Ator80 group | |
|---|----------------|----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |

Frequency threshold for reporting non-serious adverse events: 1 %

| Non-serious adverse events | Ator40 group | Ator80 group | |
|---|-----------------|----------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 5 / 13 (38.46%) | 1 / 13 (7.69%) | |
| Nervous system disorders | | | |
| cephalea | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 13 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 13 (7.69%) | |
| occurrences (all) | 0 | 1 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 13 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nausea | | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 13 (0.00%) 0 | |
| Renal and urinary disorders Renal colic subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 13 (0.00%) 0 | |
| Endocrine disorders Pancreatitis subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 13 (0.00%) 0 | |
| Infections and infestations Sputum purulent subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 13 (0.00%) 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 12 September 2005 | Protocol amendment according to EC clarifications |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported